Mustang Bio Inc

-0.05 (-2.26%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Mustang Bio Inc Stock, NASDAQ:MBIO

377 Plantation Street, 9th floor, Worcester, Massachusetts 01605-2245
United States of America
Phone: +1.781.652.4500
Number of Employees: 62


Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.